Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by American Century Companies Inc.

American Century Companies Inc. boosted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 61.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 928,286 shares of the company's stock after acquiring an additional 353,511 shares during the period. American Century Companies Inc. owned about 1.56% of Protagonist Therapeutics worth $35,832,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Summit Global Investments acquired a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $909,000. Teacher Retirement System of Texas increased its position in Protagonist Therapeutics by 18.7% during the fourth quarter. Teacher Retirement System of Texas now owns 13,099 shares of the company's stock worth $506,000 after buying an additional 2,067 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock worth $779,000 after acquiring an additional 278 shares during the last quarter. Cibc World Markets Corp purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at $211,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Protagonist Therapeutics by 35.0% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 310,650 shares of the company's stock valued at $11,963,000 after acquiring an additional 80,536 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Remove Ads

Analyst Ratings Changes

PTGX has been the subject of several analyst reports. JMP Securities reissued a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Tuesday, March 11th. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. StockNews.com cut shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Finally, HC Wainwright reissued a "buy" rating and set a $54.00 price target on shares of Protagonist Therapeutics in a research note on Monday, March 10th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Protagonist Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $62.56.

Insider Buying and Selling

In related news, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now owns 83,892 shares in the company, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the sale, the director now directly owns 13,130 shares of the company's stock, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,776 shares of company stock valued at $3,585,010. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Stock Up 2.8 %

Shares of NASDAQ PTGX traded up $1.32 during trading on Wednesday, hitting $48.20. 1,223,111 shares of the company traded hands, compared to its average volume of 801,509. The firm has a market capitalization of $2.96 billion, a P/E ratio of 18.12 and a beta of 2.34. The company has a 50-day moving average price of $43.17 and a 200-day moving average price of $42.92. Protagonist Therapeutics, Inc. has a 1 year low of $24.22 and a 1 year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.